Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: action required at the system, provider, and patient levels
about
Barriers to hepatitis C antiviral therapy in HIV/HCV co-infected patients in the United States: a reviewAccess to treatment for Hepatitis C among injection drug users: results from the cross-sectional HOPE IV study.The hepatitis C cascade of care among HIV infected patients: a call to address ongoing barriers to care.HIV and HCV coinfection: prevalence, associated factors and genotype characterization in the Midwest Region of Brazil.A descriptive model of patient readiness, motivators, and hepatitis C treatment uptake among Australian prisoners.Differences in outpatient care and treatment utilization for patients with HIV/HCV coinfection, HIV, and HCV monoinfection, a cross-sectional studyResults from a Geographically Focused, Community-Based HCV Screening, Linkage-to-Care and Patient Navigation ProgramInjecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C.Hepatitis C treatment initiation in HIV-HCV coinfected patients.Genotypic distribution and hepatic fibrosis among HIV/HCV co-infected individuals in Southern China: a retrospective cross-sectional studySelf-Reported HIV and HCV Screening Rates and Serostatus Among Substance Abuse Treatment Patients.The Impact of Direct-Acting Antivirals in the Hepatitis C-Sustained Viral Response in Human Immunodeficiency Virus-Infected Patients With Ongoing Barriers to Care.Non-initiation of hepatitis C virus antiviral therapy in patients with human immunodeficiency virus/hepatitis C virus co-infection.Improving Screening Methods for Hepatitis C Among People Who Inject Drugs: Findings from the HepTLC Initiative, 2012-2014.Factors associated with uptake, adherence, and efficacy of hepatitis C treatment in people who inject drugs: a literature review.The Population Level Cascade of Care for Hepatitis C in British Columbia, Canada: The BC Hepatitis Testers Cohort (BC-HTC)Update on HIV/HCV coinfection.Hepatitis C virus therapeutic development: in pursuit of "perfectovir".Hepatitis C and HIV Coinfection for Social Workers in Public Health, Medical and Substance Use Treatment Settings.Modeling hepatitis C virus transmission among people who inject drugs: Assumptions, limitations and future challenges.Direct-acting antiviral agents for HCV infection affecting people who inject drugs.Initiating HCV treatment with direct acting agents in opioid agonist treatment: When to start for people co-infected with HIV?Safety and efficacy of elbasvir and grazoprevir for treatment of hepatitis C.High prevalence of willingness to use direct-acting antiviral-based regimens for hepatitis C virus (HCV) infection among HIV/HCV coinfected people who use drugs.European AIDS Clinical Society Standard of Care meeting on HIV and related coinfections: The Rome Statements.Limited provision of diagnostic services to Victorians living with hepatitis C antibodies, 2001-2012: a multi-level modelling analysis.Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999-2011."Tweak Your Order Set!" Implementation of Modified Laboratory Order Set Improves Hepatitis C Virus Screening Rates in People Living With Human Immunodeficiency Virus.Attitudes and potential barriers towards hepatitis C treatment in patients with and without HIV coinfection.Cost-effectiveness of treating chronic hepatitis C virus with direct-acting antivirals in people who inject drugs in Australia.Effect of treatment willingness on specialist assessment and treatment uptake for hepatitis C virus infection among people who use drugs: the ETHOS study.Hepatitis C in a new therapeutic era: Recontextualising the lived experience.Continued low uptake of treatment for hepatitis C virus infection in a large community-based cohort of inner city residents.Need of righteous attitudes towards eradication of hepatitis C virus infection in Latin America.The forgotten component in the staging and management of HIV/hepatitis C virus-coinfected patients.The 3rd Canadian Symposium on Hepatitis C Virus: expanding care in the interferon-free era.Eliminating hepatitis C virus as a public health threat among HIV-positive men who have sex with men: a multi-modelling approach to understand differences in sexual risk behaviour.Pegylated interferon alpha 2a for the treatment of hepatitis C virus infection.Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada.Prevalence of Hepatitis C Screening, Testing, and Care Experience Among Young Adults Who Use Prescription Opioids Nonmedically.
P2860
Q27010548-F8F20B36-8E79-44F9-8BC0-668A52219A1DQ33802414-9D03AAC8-8B5B-4F78-950C-8645278CACD6Q33921543-0C961097-C2C0-4B90-B193-BD7E3516EF3BQ34977282-1A946A82-A41C-4BC6-8188-03CD01EB7B4BQ35105946-E8F42810-FA18-41C5-91A5-D00C8A6D754BQ35154639-4A0594A7-B951-4FBA-AA7A-A35523D60892Q35752660-BAE1DFA7-54B2-4439-B2AB-42202D54456FQ36079786-67D88979-AFEE-426E-A153-12848F5ECD34Q36083688-D852E7D0-E600-4392-BA35-10C3733876FAQ36110233-3F2FEC7B-9096-468E-B4B9-64AEEE810FE7Q36260469-8F848FAD-C529-4239-ACEE-E4B55E538634Q36382060-6921E751-88EA-4613-B4F9-ADE3F0AB9C71Q36654120-033BB192-A720-4BC8-8C53-911E0E00651FQ36858894-5605DA41-B512-4769-B052-F4E5AA5E80B8Q37245420-AA621E9A-AAC7-419E-9E38-7E597B07A167Q37363491-BD7200EA-DD64-48F3-8A47-11C7A01BE2E9Q38119893-25B9DD54-3B12-4A5E-8DEC-CF6682D93AACQ38374284-4C57F33F-865C-43F0-9AA1-2321ACFD52D1Q38391718-F8CF38AB-97EF-4B50-8174-890A13238EC9Q38573508-B72F09EC-151F-4BA0-9203-4AB61FB0A8ACQ38613271-9D1B8AD7-9680-4FCC-92C1-36DD8B030151Q38746105-448671F9-E30D-4CCC-A800-98481CC6916DQ38811486-EF261619-EDF9-4C96-BD94-F0AB160F4031Q38907436-E3A3912B-73D7-4176-9667-758A5ACAA8ECQ38950820-65C4BE4B-29CB-47FD-B197-6D16F7671BFBQ39138754-619086D0-9B78-49A2-8469-83788043B1AAQ39269740-33DD25BD-3B50-428D-8D53-599E8281AD57Q40065615-85F0F883-F526-497E-B6D6-249B2BFD48FDQ40078485-8B0784F7-3639-4395-9DF1-D5CC81237443Q40931707-AC5F6F6B-95C9-4BA1-96CA-CA09985744EEQ41210837-2CB66B93-BFFA-43EA-8560-2FBB060570B6Q41928113-82909EA1-6307-4A79-A71B-3D309E6BFF5AQ42259402-406B3654-DBC3-474F-A4B5-D254A6B4A3D8Q42741292-B5694613-4BB7-4E6C-B6B1-17385F1F4773Q42791908-8B935E59-0160-4A69-A93E-329FDE7BC5E6Q42955909-6204C2CD-A6F6-4408-85CB-58F6375B5A3DQ47191023-2A493627-3A17-4832-B831-C219A83FCC97Q47561313-C4F346A5-8DE6-4F7D-9177-F914ECF46352Q47565629-4F17ACF7-D248-4F5A-9CE0-629B99DBB268Q47590769-D33789C3-63C9-4223-8097-8E689E244DAB
P2860
Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: action required at the system, provider, and patient levels
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Breaking down the barriers to ...... , provider, and patient levels
@ast
Breaking down the barriers to ...... , provider, and patient levels
@en
type
label
Breaking down the barriers to ...... , provider, and patient levels
@ast
Breaking down the barriers to ...... , provider, and patient levels
@en
prefLabel
Breaking down the barriers to ...... , provider, and patient levels
@ast
Breaking down the barriers to ...... , provider, and patient levels
@en
P2093
P2860
P356
P1476
Breaking down the barriers to ...... , provider, and patient levels
@en
P2093
Gregory J Dore
Jason Grebely
Lynn E Taylor
Megan Oser
P2860
P304
P356
10.1093/INFDIS/JIS928
P407
P478
207 Suppl 1
P577
2013-03-01T00:00:00Z